<table border="single" id="id_11289ef4-90ca-47b4-a553-7bb68d8ffbf0" width="357" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_f0ba237e-1592-476b-bcfa-e6533cf251f7">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="38.1%"></col>
<col width="26.6%"></col>
<col width="35.3%"></col>
<tbody>
<tr id="id_21535ee8-9146-4299-9040-f6ff12874d46">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Clinical Comment</td>
</tr>
<tr id="id_86012b3a-4125-46a2-995a-9aad40ac9be2">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine levels approximately 50%. </td>
</tr>
<tr id="id_06cb6c7e-ee93-47c8-b23a-e0c83aba3d18">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_3e74beb0-c494-48de-bc8b-0491f957263f">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_fe9c0162-36fc-489d-ae1c-db4f257af495">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels. </td>
</tr>
<tr id="id_ed965faf-e71e-427a-af24-f54608fbf443">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_9c904546-4e6e-4393-be3f-ec64aad921a9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_a484a6ad-67e5-4c63-8af6-c2d794754794">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr id="id_b3640712-e0c0-425f-8f33-e627d70d075f">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2 fold. </td>
</tr>
<tr id="id_e8decfe9-9da5-4895-afdc-159f14e1e0e0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3 week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>